Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5615420 | Journal of Clinical Lipidology | 2016 | 11 Pages |
Abstract
Gemcabene as add-on to stable statin therapy demonstrated additional dose-dependent and statistically significant reductions in LDL-C of >20% and CRP >40% compared to placebo. The results support gemcabene-continued development for patients requiring LDL-C lowering beyond that provided by background statin therapy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Evan MD, Harold MD, Michael MD, Rebecca RPh, MS, Charles PhD,